Exagen Inc. (XGN)

Market Cap	37.52M
Revenue (ttm)	45.56M
Net Income (ttm)	-47.39M
Shares Out	16.83M
EPS (ttm)	-2.77
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,793
Open	2.26
Previous Close	2.25
Day's Range	2.16 - 2.26
52-Week Range	2.04 - 9.20
Beta	1.27
Analysts	Buy
Price Target	6.63 (+197.31%)
Earnings Date	May 9, 2023

About XGN

Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue dis...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Sep 19, 2019
• Employees: 219
• Stock Exchange: NASDAQ
• Ticker Symbol: XGN

Financial Performance

In 2022, Exagen's revenue was $45.56 million, a decrease of -5.66% compared to the previous year's $48.30 million. Losses were -$47.39 million, 76.5% more than in 2021.

Analyst Forecast

According to 10 analysts, the average rating for XGN stock is "Buy." The 12-month stock price forecast is $6.63, which is an increase of 197.31% from the latest price.

Price Target

$6.63

(197.31% upside)

Analyst Consensus: Buy